Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99.27 USD | +1.60% | +2.99% | -1.52% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.11 for the 2024 fiscal year.
- The opinion of analysts covering the stock has improved over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.52% | 24.18B | C+ | ||
+23.03% | 74.04B | C+ | ||
+3.67% | 8.46B | C | ||
+8.55% | 8.34B | B | ||
-23.71% | 7.64B | B- | ||
+15.20% | 5.33B | B- | ||
-6.90% | 3.92B | B- | ||
+2.68% | 4.12B | B | ||
+5.56% | 3.89B | B+ | ||
+18.80% | 3.54B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CAH Stock
- Ratings Cardinal Health, Inc.